26A7 Aplin, Andrew E. - Thomas Jefferson University - Thomas Jefferson University

Andrew E. Aplin, PhD

Contact Dr. Aplin

Kimmel Cancer Center
233 S. Tenth Street, Suite 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. Fibroblast-derived neuregulin 1 promotes Compensatory ErbB3 receptor signaling in mutant BRAF melanoma
  2. PAX3 and FOXD3 promote CXCR4 expression in melanoma
  3. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas
  4. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  5. Animal experimentation - questioned again!
  6. The value of thesis advisers
  7. RAC1 P29S regulates PD-L1 expression in melanoma
  8. NF-κB regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma
  9. What shall we do this year?
  10. Game of isoforms: PI3K β-sparing inhibitor is coming
  11. The value of thesis advisers
  12. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  13. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox
  14. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells
  15. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor
  16. Resistance to RAF inhibitors revisited
  17. FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma
  18. Unmet needs in melanoma research
  19. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma
  20. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors